Covering a number of hot topics and delivered by patient groups, sponsors and leading solution providers, choose which two roundtable discussions you would like to join, for ‘off the beaten track’ learning and information you can’t find online. Each session will last 40 minutes so you can join two discussions in the allotted time. The same roundtables will be run twice back to back.
Practical and operational issues around the execution of vaccine trials from a site and sponsor perspective
Adam Larrabee, President, Rochester Clinical Research, Inc
Dr Gray Happner, CMO, NewLink Genetics
Insights in International Alliance for Biological Standardization(IABS) and WHO discussions for successful regulatory use of challenge studies
Bruno Speder, Head Clinical Regulatory Affairs, Head Registration & Post Marketing Regulatory Affairs, SGS Life Sciences
Best practices for a successful CRO/Pharma partnership for vaccine clinical studies
Lynlee Burton, Director of Project Delivery, PRA Health Sciences
Managing your cold chain – Lessons learned from the Ebola clinical trials
Daniel J. Littlefield, CFO, Principal, Modality Solutions
Gaining a lead on infectious diseases: Building a global bio-intelligence-network and repository
Dr Leslie Lobel, Senior Medical Advisor – Medical Expert Office, ClinicalRM
Clinical Development & trials: Conducting clinical trials in low resource settings
Karen McCarthy, Senior Director of Project Management, PPD Vaccines
Combatting emerging viruses in a globalising world
Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover
Discovering pre-clinical genomic biomarkers of safety and efficacy in vaccine research, design and development
Dr I-Ming Wang, Associate Scientific Director, Principal Scientist, Molecular Profiling Site Lead, Merck & Co.
Round 1: Can we better characterize Glycoconjugate vaccines?
Round 2: Do we need a "Conjugate Vaccine Industry Forum"?
Dr Basav Ghosh, Senior Director, Manufacturing Sciences and Technology & Dr Bo Arve, Executive Director, BioPharmaceutical Sciences, Pfizer
Successful approaches to the conduct of global clinical vaccine studies
Cindy Dukes, VP, Global Project Management, ICON Clinical Research
From start-up to MTA with big pharma: Establishing patents, preclinical functional biomarkers, and development check points
Dr Michael Vajdy, Co-founder, Principal and CSO. EpitoGenesis, Inc.
Why are the antivaxxers winning and how can they be stopped?
Dr Peter Hotez, President of the Sabin Vaccine Institute & Dean of National School of Tropical Medicine, Baylor College of Medicine
Factors of importance for Biotechs to use in identifying, prioritizing and financing new vaccine targets
Dr Peter Nara, President & Chief Executive Officer, Biological Mimetics
Addressing the need for rapid sample sharing during emerging infectious disease outbreaks – lessons from the Zika outbreak
Dr Mukul Ranjan, Senior Advisor for Innovation and Technology Transfer, Technology Transfer and Intellectual Property Office, NIAID
Adjuvants and technology advancements driving vaccine R&D
Dr Michel De Wilde, Former Senior Vice President R&D of Sanofi Pasteur & Owner, MDW Consultant LLC
Computational vaccinology - immune engineering vaccines
Dr Anne De Groot, CEO/CSO, EpiVax